Immunomonitoring and multiple myeloma: impact of lenalidomide on immune checkpoint expression - IMMUNO-MYELO

CHU Rennes0 个研究点目标入组 22 人开始时间: 2021年3月15日最近更新: 2024年5月21日

适应症

试验速览

暂无简介。

•- Patient with newly diagnosed multiple myeloma;
•- Patient not eligible for intensive treatment;
•- Patient for whom first-line treatment with Lenalidomide-Dexamethasone will be initiated;
•- Patient accepting the performance of an additional myelogram at the end of the 1st treatment cycle.
•- Patient aged 18 years or older;
•- Patient who has given free, informed and written consent;
•- Patient affiliated to a social security scheme
•- For women of childbearing age, use of effective contraception
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 2
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•- Patient with relapsed multiple myeloma;
•- Patient eligible for intensive treatment;
•- Patient for whom chemotherapy involves treatment other than Lenalidomide-Dexamethasone;
•- Patient with a contraindication to lenalidomide treatment
•- Pregnant or breastfeeding woman;
•- Person subject to legal protection (safeguard of justice, curatorship, guardianship) or person deprived of liberty.

发起方